Trendlines reported a FY 2025 net profit attributable to equity holders of USD 1.9 million, compared with a loss of USD 9.4 million in FY 2024, as it posted total income of USD 9.9 million and income before tax of USD 1.5 million. The group recorded a net gain in the fair value of portfolio companies of USD 7.1 million in FY 2025. IFRS portfolio fair value was USD 76.5 million as at 31-Dec-25, up 15.7%, while non-IFRS portfolio fair value was USD 127.7 million as at 31-Dec-25. Total assets rose 13.9% to USD 85.8 million, with investments in portfolio companies up 15.7% to USD 76.5 million; total current liabilities increased 23.1% to USD 4.8 million and total equity rose 13.7% to USD 77.4 million, while net asset value per share was USD 0.06. During FY 2025, Trendlines said its rights issue to raise about SGD 3.9 million was oversubscribed by about 25%, and it raised about SGD 6.4 million via private placements. Portfolio updates included IBI Ag’s USD 10 million Series A round, Escala Medical’s USD 4.5 million funding round, Limaca Medical’s launch of US sales for its endoscopic EUS biopsy device and a subsequent US distribution agreement, Arcuro Medical’s Series A funding and FDA clearance for its rotator cuff treatment product, and a joint development and commercial agreement between SOLVEAT and CBC Group. Post-2025, Trendlines said Phytolon received FDA clearance for its Beetroot Red natural food color, enabling commercialization in the US in 2026, subject to the standard public comment period. CEO Haim Brosh cited operational streamlining and focus on high-potential portfolio companies as drivers of the return to profitability.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trendlines Group Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: GKDDK032G7ZW5LRX) on February 24, 2026, and is solely responsible for the information contained therein.